In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

Session New concepts in pulmonary hypertension

Speaker Stephan Rosenkranz

Event : ESC Congress 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Hypertension
  • Session type : Abstract Sessions

Authors : S Rosenkranz (Cologne,DE), R Channick (Los Angeles,US), K Chin (Dallas,US), B Jenner (Allschwil,CH), S Gaine (Dublin,IE), N Galie (Bologna,IT), HA Ghofrani (London,GB), M M Hoeper (Hannover,DE), V V Mclaughlin (Ann Arbor,US), R Preiss (Allschwil,CH), L J Rubin (San Diego,US), G Simonneau (Le Kremlin Bicetre,FR), O Sitbon (Le Kremlin Bicetre,FR), V Tapson (Los Angeles,US), I M Lang (Vienna,AT)

S. Rosenkranz1 , R. Channick2 , K. Chin3 , B. Jenner4 , S. Gaine5 , N. Galie6 , H.A. Ghofrani7 , M.M. Hoeper8 , V.V. McLaughlin9 , R. Preiss4 , L.J. Rubin10 , G. Simonneau11 , O. Sitbon11 , V. Tapson12 , I.M. Lang13 , 1University of Cologne - Cologne - Germany , 2University of California Los Angeles - Los Angeles - United States of America , 3UT Southwestern Medical Centre - Dallas - United States of America , 4Actelion Pharmaceuticals Ltd - Allschwil - Switzerland , 5Mater Misericordiae University Hospital - Dublin - Ireland , 6University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine - DIMES - Bologna - Italy , 7University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center for Lung Research, and Department of Medicine, Imperial College London - London - United Kingdom , 8Department of Respiratory Medicine, Hannover Medical School and German Center for Lung Research - Hannover - Germany , 9University of Michigan - Ann Arbor - United States of America , 10Division of Pulmonary and Critical Care Medicine, University of California - San Diego - United States of America , 11Hopital Universitaire de Bicetre, Universite Paris-Sud - Le Kremlin Bicetre - France , 12Cedars-Sinai Medical Center - Los Angeles - United States of America , 13Division of Cardiology, Medical University of Vienna - Vienna - Austria ,

Pulmonary Hypertension

European Heart Journal ( 2019 ) 40 ( Supplement ), 3038

Introduction: Many PAH patients today have a number of CV comorbidities, yet data on the efficacy and safety of therapies in such patients remain scarce. Most recent PAH clinical trials also include patients with comorbidities.

Purpose: To assess the long-term efficacy and safety of the oral, selective IP prostacyclin receptor agonist, selexipag, in PAH patients with and without significant CV comorbidities using post hoc analysis of GRIPHON data.

Methods: GRIPHON enrolled 1156 PAH patients randomised 1:1 to placebo:selexipag. The present analysis includes patients with right heart catheterisation within 1 year of randomisation who were categorised as with or without CV comorbidities. Patients with CV comorbidities were defined as having ≥3 of the following: body mass index (BMI) >30 kg/m2, history of essential hypertension, diabetes mellitus, or historical evidence of significant coronary artery disease; if PAWP/LVEDP was >12 but <15 mmHg, pulmonary vascular resistance (PVR) had to be >500 dyn.sec/cm5; if PAWP/LVEDP was <12, then PVR had to be >300 dyn.sec/cm5. Selexipag effect on time to first morbidity/mortality (M/M) event up to end of treatment was assessed for both subgroups. Baseline (BL) adjusted treatment hazard ratios with 95% CIs were calculated using Cox models. Model building involved stepwise backward elimination of BL covariates.

Results: 752 PAH patients could be categorised based on these criteria (99 with CV comorbidities, 653 without). At BL, patients with CV comorbidities were older (median [range] 60 [28–80] vs 46 [18–78] yrs), had higher BMI (mean [SD] 33.3 [7.23] vs 26.0 [5.64] kg/m2) and lower 6-minute walk distance (mean [SD] 319 [95.7] vs 354 [79.3] m) vs those without. A greater proportion were from Western Europe/Australia/North America (60.6% vs 38.9%) and in WHO functional class III (69.7% vs 49.9%). At BL, 82.8% of patients with CV comorbidities were receiving PAH therapies vs 75.7% of those without. As expected, at BL a higher proportion of patients with CV comorbidities (vs without) had previous/concomitant cardiac disease (62.6% vs 43.0%), metabolism/nutrition disorders (75.8% vs 31.2%), respiratory/thoracic/mediastinal disorders (59.6% vs 37.5%) and vascular disorders (76.8% vs 37.4%). Selexipag reduced the risk of M/M events vs placebo in both subgroups (Figure), with no evidence of an inconsistent treatment effect (interaction p-value=0.1544). Adverse events leading to treatment discontinuation were reported in 35.4% (25.9% selexipag, 46.7% placebo) of patients with CV comorbidities and 35.0% (32.0% selexipag, 38.0% placebo) of those without. Common prostacyclin associated side effects observed with selexipag (headache, diarrhoea, nausea) were reported at a similar incidence in both subgroups.

Conclusions: Selexipag had a beneficial effect on long-term outcome in PAH patients both with and without CV comorbidities. Safety in both groups was consistent with the known profile of selexipag.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are